🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Plasma and Radiologic Biomarkers of Response to ECP in Lung Transplant Recipients With CLAD

Recruitingn/aAges 7 Years - anyAllBrian Keller
NCT07434869 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study is for people who have had a lung transplant and developed a condition called chronic lung allograft dysfunction (CLAD), which is a type of chronic rejection. Doctors often treat CLAD with a procedure called extracorporeal photopheresis (ECP), but it can take up to six months to know if the treatment is working. The goal of the study is to find early signs (biomarkers) that show whether ECP is helping, so patients can get the right care sooner. For participants in the study, small blood samples will be collected at three points during ECP treatment and, for some participants, two MRI scans of the lungs will be performed-one before starting ECP and one after finishing treatment. The MRI uses a safe contrast dye to help us see changes in lung blood flow and tissue. Investigators will also look at certain immune cells in the blood. This is not a study of a new drug or treatment

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adults (≥18 years) or pediatric patients (7-17 years) who have had a single or double lung transplant * Diagnosed with CLAD (any stage) and prescribed ECP therapy * Ability to provide informed consent (or assent with parental consent for minors) Exclusion Criteria: * Previously received ECP treatment * Receipt of anti-thymocyte globulin within 3 months or alemtuzumab within 12 months of ECP initiation * Contraindications to MRI (for MRI subgroup), including metal implants, claustrophobia, seizure disorder * Known allergy to gadolinium or impaired kidney function (eGFR \<30 ml/min) * Pregnant or breastfeeding
💊

What it tests

  • Not listed
📍

Where

3 sites
Massachusetts General Hospital
Boston, United States
Brigham and Women's Hospital
Boston, United States
The Ohio State University Wexner Medical Center
Columbus, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy